4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $19,947.00 in Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 1,635 shares of the company’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $12.20, for a total transaction of $19,947.00. Following the completion of the transaction, the insider owned 8,617 shares in the company, valued at approximately $105,127.40. This trade represents a 15.95% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Scott Bizily also recently made the following trade(s):

• On Thursday, August 13th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.00, for a total value of $19,620.00.
• On Tuesday, June 23rd, Scott Bizily sold 9,810 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.00, for a total value of $117,720.00.

4D Molecular Therapeutics Stock Performance

NASDAQ:FDMT traded up $2.36 during mid-day trading on Monday, hitting $14.55. 3,444,983 shares of the stock were exchanged, compared to its average volume of 805,311. The firm’s 50-day simple moving average is $10.94 and its 200 day simple moving average is $9.89. The stock has a market capitalization of $760.67 million, a price-to-earnings ratio of -5.53 and a beta of 2.73. 4D Molecular Therapeutics, Inc. has a fifty-two week low of $5.97 and a fifty-two week high of $15.03. The company has a debt-to-equity ratio of 0.05, a quick ratio of 8.03 and a current ratio of 8.03.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.02). The firm had revenue of $3.78 million during the quarter, compared to analyst estimates of $3.62 million. 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. As a group, equities analysts anticipate that 4D Molecular Therapeutics, Inc. will post -3.88 EPS for the current fiscal year.

Analyst Ratings Changes

FDMT has been the subject of several analyst reports. Wall Street Zen cut shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. B. Riley Financial reissued a “buy” rating on shares of 4D Molecular Therapeutics in a research report on Monday. Chardan Capital raised 4D Molecular Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Friday, July 17th. Finally, The Goldman Sachs Group reissued a “buy” rating and set a $32.00 target price on shares of 4D Molecular Therapeutics in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, 4D Molecular Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $29.62.

Institutional Trading of 4D Molecular Therapeutics

Large investors have recently made changes to their positions in the company. Persistent Asset Partners Ltd acquired a new stake in 4D Molecular Therapeutics in the second quarter valued at about $1,936,000. Dimensional Fund Advisors LP lifted its holdings in shares of 4D Molecular Therapeutics by 77.3% in the first quarter. Dimensional Fund Advisors LP now owns 522,823 shares of the company’s stock worth $4,863,000 after acquiring an additional 227,982 shares during the last quarter. Exome Asset Management LLC bought a new position in shares of 4D Molecular Therapeutics in the first quarter worth about $1,216,000. Evergreen Quality Fund GP Ltd. acquired a new stake in shares of 4D Molecular Therapeutics in the 4th quarter valued at approximately $7,136,000. Finally, Simplify Asset Management Inc. bought a new stake in shares of 4D Molecular Therapeutics during the 1st quarter valued at approximately $656,000. Institutional investors and hedge funds own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.